Skip to Content

Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$371.00CflsDnztchwcn

Merck: Posts Leading Early-Stage Keytruda Data in Lung Cancer, Creates Important Daiichi Partnership

We are holding firm to our Merck fair value estimate following the presentation of leading efficacy data for Keytruda in periadjuvant non-small-cell lung cancer and the announcement of a partnership with Daiichi for three new antibody-drug conjugates. Merck's continued strong innovation with Keytruda and fair deployment of capital reinforce its wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center